NCT06037252: An ongoing trial by Eli Lilly and Company
This trial is ongoing. It must report results 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06037252 |
|---|---|
| Title | A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Tirzepatide Doses in Participants With Type 2 Diabetes and Obesity |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 21, 2023 |
| Completion date | Jan. 8, 2026 |
| Required reporting date | Jan. 8, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |